[1] Diehl M,Risse JH,Brandt-MainzK,et al.Fluorine-18fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicenter study[J]. Eur J Nucl Med,2001,28(11): 1671-1676.
[2] Moog F,Linke R,Manthey N,et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma[J]. J Nucl Med,2000, 41(12): 1989-1995.
[3] Shiga T,Tsukamoto E,Nakada K,et al. Comparison of 18F-FDG,131I-Na,and 201Tl in diagnosis of recurrent or metastatic thyroid carcinoma[J]. J Nucl Med,2001,42(3): 414-419.
[4] Neumann DR,Esselstyn CB,MacIntyre WJ,et al. Primary hyperparathyroidism: preoperative parathyroid imaging with regional body FDG PET[J]. Radiology,1994, 192(2): 509-512.
[5] MelonP,Luxen A,Hamoir E,et al. Fluorine-18-fluorodeoxyglu-cose positron emission tomography fr preoperative parathyroid imaging in primary hyperparathyroidism[J]. Eur J Nucl Med, 1995, 22(6): 556-558.
[6] Neumann DR, Esselstyn CB, MacIntyre WJ, et al. Compari-son of FDG-PET and seatamibi-SPECT in primary hyper-parathyroidism[J]. J Nucl Med,1996,37(11): 1809-1815.
[7] Bergstrom M, Juhlin C, Bonasera TA, et al. PET imaging ofadrenal cortical tumors with the 11β-Hydroxylase tracer 11C-Metomidate[J]. J Nucl Med,2000, 41(2): 275-282.
[8] Shulkin BL, Thompson NW, Shapiro B, et al. Pheochromo-cytomas: imaging with 2-[fluorine-18] fluoro-2-deoxy-D-glu-cose PET[J]. Radiology,1999, 212(7): 35-41.
[9] Yun M,Kim W,Alnafisi N,et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI[J]. J Nucl Med,2001,42(12): 1795-1799.
[10] Shulkin BL,Hutchinson RJ,Castle VP,et al. Neuroblas-toma: positron emission tomography with 2-[fluorine-18] fluoro-2-deoxy-D-glucose compared with metaiodobenzylguani-dine scintigraphy[J]. Radiology,1996, 199(3): 743-750.
[11] Shulkin BL, Wieland DM, Baro ME, et al. PET hydrox-yphedrine imaging of neuroblastoma[J]. J Nucl Med, 1996, 37(1): 16-21.